The integration of rapid drug resistance detection via enzyme activation into point-of-care testing (POCT) systems holds immense potential for clinical diagnostics, particularly in resource-limited settings. The rapid genotyping platform developed by Cheng et al. (2022) combines allele-specific PCR and lateral flow assays for detecting chloroquine resistance in Plasmodium falciparum, underscoring the utility of enzyme-related mechanisms in enhancing POCT capabilities [8]. Rapid, accurate diagnostics at the point of care facilitate immediate treatment decisions, improving patient management and contributing to the control of infectious diseases.
The integration of rapid drug resistance detection through enzyme activation into point-of-care testing systems, exemplified by Cheng et al.'s (2022) innovative platform that utilizes allele-specific PCR and lateral flow assays to identify chloroquine resistance in Plasmodium falciparum, significantly enhances clinical diagnostics in resource-limited settings by enabling swift and precise treatment decisions that improve patient management and aid in the control of infectious diseases.